Dalziel SR, et al. - For pediatric convulsive status epilepticus, researchers ascertained if phenytoin or levetiracetam is superior as second-line treatment. For this open-label, multicenter, randomized controlled trial, children (aged between 3 months and 16 years) with convulsive status epilepticus that failed first-line benzodiazepine treatment were randomly assigned (1:1) via a computer-generated permuted block (block sizes 2 and 4) randomization sequence, stratified by site and age (≤5 years, >5 years), to receive 20 mg/kg phenytoin (intravenous or intraosseous infusion over 20 min) or 40 mg/kg levetiracetam (intravenous or intraosseous infusion over 5 min). For second-line management of epileptic pediatric convulsive status, levetiracetam is not superior to phenytoin.